A detailed history of Franklin Resources Inc transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Franklin Resources Inc holds 94,659 shares of LGND stock, worth $10.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
94,659
Previous 94,659 -0.0%
Holding current value
$10.7 Million
Previous $9.48 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$82.7 - $110.11 $6.53 Million - $8.7 Million
78,973 Added 503.46%
94,659 $9.48 Million
Q2 2024

Aug 14, 2024

BUY
$68.53 - $87.91 $119,721 - $153,578
1,747 Added 12.53%
15,686 $1.32 Million
Q1 2024

May 13, 2024

SELL
$68.64 - $89.2 $8,717 - $11,328
-127 Reduced 0.9%
13,939 $1.02 Million
Q4 2023

Feb 09, 2024

BUY
$49.57 - $72.63 $21,711 - $31,811
438 Added 3.21%
14,066 $1 Million
Q3 2023

Nov 13, 2023

BUY
$58.86 - $72.67 $246,682 - $304,559
4,191 Added 44.41%
13,628 $816,000
Q2 2023

Aug 11, 2023

BUY
$69.53 - $79.33 $656,154 - $748,637
9,437 New
9,437 $680,000
Q2 2022

Aug 11, 2022

SELL
$74.52 - $117.06 $22,132 - $34,766
-297 Reduced 11.55%
2,275 $203,000
Q1 2022

May 13, 2022

BUY
$94.99 - $151.56 $2,944 - $4,698
31 Added 1.22%
2,572 $290,000
Q4 2021

Feb 11, 2022

BUY
$127.69 - $165.85 $24,516 - $31,843
192 Added 8.17%
2,541 $392,000
Q3 2021

Nov 12, 2021

BUY
$102.33 - $144.73 $80,943 - $114,481
791 Added 50.77%
2,349 $328,000
Q2 2021

Aug 13, 2021

BUY
$113.03 - $155.64 $11,303 - $15,563
100 Added 6.86%
1,558 $204,000
Q1 2021

May 13, 2021

BUY
$99.52 - $215.83 $145,100 - $314,680
1,458 New
1,458 $223,000

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.91B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Franklin Resources Inc Portfolio

Follow Franklin Resources Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

News

Stay updated on Franklin Resources Inc with notifications on news.